Capricor Therapeutics, Inc. (CAPR) SEC filings

CAPRNasdaqPharmaceutical PreparationsFiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 10, 2026Score 5/30

$9.53−0.71 (-6.93%)

Close on Nov 13, 2026Market cap $554.07MP/E –Yield –

SEC filings

40 of Capricor Therapeutics's most recent filings on SEC EDGAR

Document	Form	Period	Filed	Source
Quarterly report	10-Q	Sep 30, 2026	Nov 10, 2026	SEC EDGAR
Current report	8-K	Nov 10, 2026	Nov 10, 2026	SEC EDGAR
Current report	8-K	Aug 24, 2026	Aug 24, 2026	SEC EDGAR
Quarterly report	10-Q	Jun 30, 2026	Aug 14, 2026	SEC EDGAR
Current report	8-K	Aug 13, 2026	Aug 13, 2026	SEC EDGAR
Current report	8-K	Jul 29, 2026	Jul 30, 2026	SEC EDGAR
Current report	8-K	Jul 29, 2026	Jul 29, 2026	SEC EDGAR
Current report	8-K	Jul 9, 2026	Jul 14, 2026	SEC EDGAR
Current report	8-K	Jun 26, 2026	Jun 26, 2026	SEC EDGAR
Current report	8-K	Jun 4, 2026	Jun 8, 2026	SEC EDGAR
Quarterly report	10-Q	Mar 31, 2026	May 13, 2026	SEC EDGAR
Current report	8-K	May 12, 2026	May 12, 2026	SEC EDGAR
Current report	8-K	May 7, 2026	May 7, 2026	SEC EDGAR
Proxy statement	DEF 14A	Jun 4, 2026	Apr 10, 2026	SEC EDGAR
Annual report	10-K	Dec 31, 2025	Mar 17, 2026	SEC EDGAR
Current report	8-K	Mar 12, 2026	Mar 12, 2026	SEC EDGAR
Current report	8-K	Mar 10, 2026	Mar 10, 2026	SEC EDGAR
Current report	8-K	Dec 5, 2025	Dec 5, 2025	SEC EDGAR
Current report	8-K	Dec 3, 2025	Dec 3, 2025	SEC EDGAR
Current report	8-K	Dec 3, 2025	Dec 3, 2025	SEC EDGAR
Quarterly report	10-Q	Sep 30, 2025	Nov 10, 2025	SEC EDGAR
Current report	8-K	Nov 10, 2025	Nov 10, 2025	SEC EDGAR
Quarterly report	10-Q	Jun 30, 2025	Aug 11, 2025	SEC EDGAR
Current report	8-K	Aug 11, 2025	Aug 11, 2025	SEC EDGAR
Current report	8-K	Jul 11, 2025	Jul 11, 2025	SEC EDGAR
Current report	8-K	May 22, 2025	May 27, 2025	SEC EDGAR
Quarterly report	10-Q	Mar 31, 2025	May 14, 2025	SEC EDGAR
Current report	8-K	May 13, 2025	May 13, 2025	SEC EDGAR
Proxy statement	DEF 14A	May 22, 2025	Apr 8, 2025	SEC EDGAR
Current report	8-K	Apr 8, 2025	Apr 8, 2025	SEC EDGAR
Annual report	10-K	Dec 31, 2024	Mar 26, 2025	SEC EDGAR
Current report	8-K	Mar 19, 2025	Mar 19, 2025	SEC EDGAR
Current report	8-K	Mar 4, 2025	Mar 4, 2025	SEC EDGAR
Current report	8-K	Jan 2, 2025	Jan 2, 2025	SEC EDGAR
Quarterly report	10-Q	Sep 30, 2024	Nov 14, 2024	SEC EDGAR
Current report	8-K	Nov 13, 2024	Nov 13, 2024	SEC EDGAR
Current report	8-K	Oct 16, 2024	Oct 17, 2024	SEC EDGAR
Current report	8-K	Oct 16, 2024	Oct 16, 2024	SEC EDGAR
Current report	8-K	Oct 9, 2024	Oct 9, 2024	SEC EDGAR
Current report	8-K	Sep 24, 2024	Sep 24, 2024	SEC EDGAR

Where these numbers come from

Parsed from the XBRL in Capricor Therapeutics's annual and quarterly filings with the SEC
Per-share figures adjusted for the 1-for-10 reverse split on Jun 5, 2019
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is CAPR.

Compare: CAPR vs PRQR · CAPR vs ARCT · CAPR vs QURE · CAPR vs CELU · CAPR vs KROS

Revenue growth-100.0% · median -58.1%

Company	Revenue	Growth
KROS	$40.42M	-83.4%
ARCT	$30.51M	-68.7%
QURE	$20.17M	+28.0%
CELU	$18.67M	-58.1%
PRQR	€18.36M	+11.4%
CAPR	$0	-100.0%

Company

Next earnings (est.): Mar 11, 2027, after close
Exchange: Nasdaq
Industry: Pharmaceutical Preparations
Fiscal year ends: December 31
Employees: 231
Held by institutions: 67.6%
Auditor: Rose, Snyder& Jacobs LLP
SEC CIK: 1133869

Advertisement
300 × 250

See a number that looks wrong?